Methylphenidate (MPH)

DRUG8 trials

Conditions

Alzheimer DementiaAlzheimer Dementia (AD)Alzheimer DiseaseAlzheimer s DiseaseApathyApathy in DementiaAttention Deficit Disorder With HyperactivityAttention Deficit Hyperactivity Disorder

Phase 1

A Multimodal Imaging Study of Dopamine in Early Psychosis

Not yet recruitingNCT06977308

New York State Psychiatric InstituteClinical High Risk for Psychosis (CHR)

Start: 2026-03-01End: 2030-10-01Target: 115Updated: 2025-12-17

Phase 2

ERP Based Single-dose Predictions of Stimulants

CompletedNCT02695355

Ostfold Hospital TrustAttention Deficit Hyperactivity Disorder

Start: 2006-10-31End: 2015-09-30Updated: 2016-03-01

Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia

RecruitingNCT07279740

Sunnybrook Health Sciences CentreAlzheimer Dementia, Alzheimer Dementia (AD), Alzheimer Disease +3

Start: 2026-01-31End: 2027-10-01Target: 12Updated: 2025-12-12

Phase 3

Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue

RecruitingNCT06905587

Odense University HospitalBrain Tumor, Pediatric, Cancer-related Fatigue, Methylphenidate

Start: 2025-09-02End: 2029-12-31Target: 50Updated: 2025-12-11

Phase 4

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

CompletedNCT00429273

University of California, Los AngelesAttention Deficit Disorder With Hyperactivity

Start: 2007-01-31End: 2011-07-31Updated: 2021-07-30

Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression

CompletedNCT00602290

University of California, Los AngelesDepression

Start: 2008-02-29End: 2013-02-28Updated: 2018-01-11

Treating Young Children With Attention Deficit Hyperactivity Disorder

Not yet recruitingNCT07300956

Children's Hospital Medical Center, CincinnatiAttention-Deficit/Hyperactivity Disorder (ADHD)

Start: 2026-02-28End: 2030-07-31Target: 370Updated: 2026-01-07

Unknown Phase

Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD

NCT02430896

Asan Medical CenterAttention Deficit Disorder With Hyperactivity

Start: 2015-02-28End: 2020-12-31Target: 600Updated: 2019-07-05

2022-08-107 citations

Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder

Journal of the American Academy of Child & Adolescent Psychiatry2022-08-0910 citations

Predicting Clinical Gains and Side Effects of Stimulant Medication in Pediatric Attention-Deficit/Hyperactivity Disorder by Combining Measures From qEEG and ERPs in a Cued GO/NOGO Task

Clinical EEG and Neuroscience2018-06-2531 citations

Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder

Journal of Child and Adolescent Psychopharmacology2016-08-0225 citations

Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.

2016-06-0719 citations

Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.

2016-06-0336 citations

Effects of d-Methylphenidate, Guanfacine, and Their Combination on Electroencephalogram Resting State Spectral Power in Attention-Deficit/Hyperactivity Disorder.

2016-05-2129 citations